ICYMI: I-MAK SURVEY FINDS FOUR IN FIVE AMERICANS SUPPORT PATENT REFORMS TO LOWER PRESCRIPTION DRUG PRICES
Nov 11, 2025
New Findings Underscore Broad-Based Support for Market-Based Solutions to Hold… Read More
© 2026 CSRXP- All Rights Reserved
Updates
BIG PHARMA EARNINGS WATCH: ASTRAZENECA
Nov 11, 2025
Major Drug Company Surpasses Wall Street Forecasts as Price Hikes Fuel Growth… Read More
BIG PHARMA EARNINGS WATCH: ABBVIE, AMGEN & PFIZER
Nov 6, 2025
Major Drug Companies Surpass Wall Street Forecasts as Price Hikes Boost… Read More
THEY SAID IT!: ADMINISTRATION HIGHLIGHTS HOW BIG PHARMA GAMES THE SYSTEM TO UNDERMINE BIOSIMILAR COMPETITION, KEEP PRESCRIPTION DRUG PRICES HIGH
Nov 6, 2025
HHS, FDA and CMS Leaders Emphasize How Streamlining Biosimilar Approvals Will… Read More
BIG PHARMA EARNINGS WATCH: GSK, MERCK, BRISTOL MYERS SQUIBB, ELI LILLY & GILEAD
Nov 3, 2025
Big Pharma Companies Beat Expectations After Hiking Prices on American… Read More
CSRxP APPLAUDS ADMINISTRATION FOR COMMITMENT TO FOSTERING GREATER BIOSIMILAR COMPETITION, LOWERING DRUG PRICES FOR AMERICAN PATIENTS
Oct 29, 2025
Efforts to Eliminate Red Tape and Boost Access to More Affordable Alternatives… Read More
CSRxP: HELP COMMITTEE SHOULD REJECT BIG PHARMA’S DEBUNKED INNOVATION RHETORIC, FOCUS ON IMPROVING COMPETITION TO HIGH-PRICED BIOLOGIC BLOCKBUSTERS
Oct 28, 2025
Lawmakers Can Add to Bipartisan Momentum for Market-Based Solutions to Foster… Read More
DOSE OF REALITY: NEW ICER REPORT FINDS BIG PHARMA CONTINUES SETTING INCREASINGLY OUT-OF-CONTROL LAUNCH PRICES UNJUSTIFIED BY CLINICAL VALUE
Oct 27, 2025
Launch Prices for 23 New Treatments Exceeding Estimates for a Fair Price Cost… Read More
DOSE OF REALITY: MERCK SURPASSES MILESTONE IN PRODUCT-HOPPING STRATEGY TO BLOCK COMPETITION, KEEP PRICES HIGH ON BLOCKBUSTER CANCER DRUG KEYTRUDA
Oct 22, 2025
DOSE OF REALITY: MERCK SURPASSES MILESTONE IN PRODUCT-HOPPING STRATEGY TO… Read More
CBO NEARLY DOUBLES COST ANALYSIS FOR BIG PHARMA’S BLOCKBUSTER BAILOUT, FINDING SENIORS AND TAXPAYERS WILL PAY $8.8 BILLION DUE TO HIGHER DRUG PRICES
Oct 20, 2025
Armed with More Accurate Information on the True Impact of Pharma-Backed… Read More
DOSE OF REALITY: CONGRESS MUST REPEAL BIG PHARMA’S BLOCKBUSTER BAILOUT THAT WILL COST SENIORS AND TAXPAYERS BILLIONS OF DOLLARS IN PREVIOUSLY UNDERESTIMATED COSTS
Oct 20, 2025
ORPHAN Cures Act Will Enable Big Pharma to Keep Drug Prices High on Top Money… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Oct 16, 2025
Big Pharma Company Beats Wall Street Expectations Following Price Hikes on… Read More